First-in-Class Antibody
Developing Novel Antibody Biologics to Address Unmet Medical Needs
Prestige Biopharma invests its expertise and resources in the development of first-in-class antibody therapeutics to fight life-threatening diseases. To bring innovation for life, we are developing novel monoclonal and bispecific antibody drugs that ensure stability and strong growth potential.
IDC005 🔍
: Highly aggressive tumors such as pancreatic cancer often feature extensive development of connective tissue, known as desmoplasia, and rapid growth of blood and lymphatic vessels, referred to as angiogenesis and lymph-angiogenesis. These processes are co-dependent. IDC005 is a bispecific antibody that targets desmoplasia and (lymph-)angiogenesis.
IDC007 🔍
: Systemic inflammatory response syndrome (SIRS) is a severe, often fatal cascade of exaggerated immune responses. It can be caused by infectious and autoimmune diseases such as COVID-19 and lupus, and immunotherapies like T-cell based therapies and immune checkpoint inhibitors. IDC007 is a bispecific antibody that suppresses two key molecules in the development of CRS.
IDC008 🔍
: More than 80% of cancer patients do not respond to treatment by immune checkpoint inhibitors, which is a challenge seen in tumors with severely immune-suppressed tumor microenvironment (TME). Another challenge is that some patients are susceptible to the drugs’ off-target adverse effects. IDC008 is a bispecific antibody that targets PAUF and an immune checkpoint molecule expressed in tumors. Targeting PAUF increases the selectivity of the immune checkpoint inhibition and alleviates TME immune suppression, at the same time.
First-in-Class Antibody Pipeline
Category
Pipeline
Indication
Development Stage
Monoclonal
Antibody
PBP1510
(Ulenistamab)
Pancreatic cancer,
Ovarian cancer
Monoclonal
Antibody
PBP1710
(Anti-CTHRC1)
Solid Tumors
Bispecific
Antibody
IDC001
Pancreatic cancer,
Ovarian cancer
Bispecific
Antibody
IDC002
Pancreatic cancer,
Ovarian cancer
Bispecific
Antibody
IDC003
Solid Tumors
Bispecific
Antibody
IDC004
Pancreatic cancer,
Ovarian cancer
Bispecific
Antibody
IDC005
Solid Tumors
Bispecific
Antibody
IDC007
Critical immune disorders
Bispecific
Antibody
IDC008
Pancreatic cancer,
Ovarian cancer
Bispecific
Antibody
IDC009
Pancreatic cancer,
Ovarian cancer
Bispecific
Antibody
IDC010
Immune diseases
Expanded Access Policy
At Prestige Biopharma, we are committed to developing safe and effective drugs to improve the health and well-being of patients. We recognize that some patients may have serious or life-threatening conditions and are not able to participate in our clinical trials. For these patients, Expanded Access to investigational drugs may be an option.
Currently, our investigational medicines are in early phase development, and we are not yet providing Expanded Access. We believe that participating in our clinical trials is the best way for patients to potentially access our investigational medicines prior to regulatory approval. We consider this approach to be the best opportunity to bring safe and effective treatments to patients. We encourage any person interested in gaining access to our investigational medicines to consult their physician regarding the possibility of participating in one of our clinical trials. Please review the information about Prestige Biopharma’s ongoing clinical trials found on this website as well as at https://clinicaltrials.gov/.
We wish to assure patients that we are constantly evaluating our policies and procedures. As such, Expanded Access may be reassessed in the future as our investigational medicines advance further in clinical trials and more data to support the safety and effectiveness becomes available.
If you have any questions about our Expanded Access policy or our clinical trials, please contact us at info@prestigebio.com.